Viatris Inc — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Viatris reported Q2 2026 revenues of $3.76B (+5% YoY) and adjusted EBITDA of $1.19B (+8% operationally), driven by growth in Greater China (+16% operational) and new product launches (~$101M Q2, $172M YTD). The company signed a definitive agreement to sell global rights to Tyrvaya to Harrow for $30M upfront plus $70M in contingent milestones, and raised full-year 2026 guidance midpoints: total revenues to $14.75B (from $14.70B), adjusted EBITDA to $4.40B (from $4.30B), and adjusted EPS to $2.52 (from $2.40). Viatris returned $550M to shareholders ($270M via share repurchases at $16.42/share), reduced gross leverage to 2.9x, and acknowledged $100-150M revenue impact from Nashik facility disruptions in H2 2026.
Why this rating
Guidance raise and margin expansion positive; but Tyrvaya divestiture ($100M GAAP charge) and supply disruptions ($100-150M revenue headwind) offset gains. Moderate event relative to $10.4B market cap.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.